There have been documented severe circumstances of peliosis hepatis, sometimes linked to liver failure and intra-abdominal hemorrhage; liver tumors, sometimes fatal; and blood lipid alterations affiliated with improved chance of atherosclerosis led FDA to remove acceptance in June 2023. Further warnings include things like the pitfalls linked to ch